Contents
Vol 2, Issue 34
Contents
Editorial
- Translational Science: A View from a Biotechnology Investor
If biotechnology is to remain a prime venue for the translation of science into innovative medical products, then the venture capital firms that fund these companies must replace deal flow business plans with idea flow approaches.
Perspectives
- Tumor-Penetrating Peptides: A Shift from Magic Bullets to Magic Guns
A two-motif cyclic peptide facilitates tumor penetration of conjugated or coadministered drugs.
- Visualizing the Landscape of Selection Biomarkers in Current Phase III Oncology Clinical Trials
A global analysis of selection biomarkers currently in use in oncology phase III clinical trials reveals a terrain that is both rich and sparse.
Research Article
- Cystamine Suppresses Polyalanine Toxicity in a Mouse Model of Oculopharyngeal Muscular Dystrophy
Mice with oculopharyngeal muscular dystrophy, caused by aggregation of a nuclear protein, show improvement when treated with cystamine, suggesting a possible therapeutic approach for patients.
Editors' Choice
- TMPRSS2-ERG, a Mover and a Shaker
TMPRSS2-ERG modulates critical pathways to promote prostate cancer progression.
- The Latest PARP Sensation
Inhibition of poly(ADP-ribose) polymerase serves as a therapy for peripheral diabetic neuropathy.
- "Drop-the-Loser" Designs—An Alternative Design for Phase III Studies
"Drop-the-loser" clinical trails offer a useful alternative to classic single-dose phase III designs when phase II data are ambiguous.
- Destination: Stent
Magnetic nanoparticles carrying a therapeutic agent can be specifically targeted to stents to prevent re-occlusion of blood vessels.
